ALLMedicine™ Cholangitis Center - Clinicaltrials.gov
This OCALIVA® (obeticholic acid) site is intended for US healthcare professionals only. See Prescribing Info & Boxed Warning.
Jan 31st, 2010 - This guideline has been approved by the American Association for the Study of Liver Diseases and represents the position of the Association. These recommendations provide a data‐supported approach.
Gideon M. Hirschfield
Mar 27th, 2018 - Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation.
Oct 31st, 2018 - This American Association for the Study of Liver Diseases (AASLD) 2018 Practice Guidance on Primary Biliary Cholangitis (PBC) is an update of the PBC guidelines published in 2009. The 2018 updated guidance on PBC includes updates on etiology and diagnosis, role of imaging, clinical manifestations, and treatment of PBC since 2009.
The American Journal of Gastroenterology; Kwo,P.,et al
Jun 30th, 2017 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with al...
JAMA Iranmanesh P, Frossard JL et. al.
Jul 9th, 2014 - The optimal management of treatment for patients at intermediate risk of a common duct stone (including increased liver function tests but bilirubin <4 mg/dL and no cholangitis) is a matter of debate. Many stones migrate spontaneously into the duodenum, making preoperative common duct investigations unnecessary. To compare strategies of cholecystectomy first vs a sequential endoscopic common du...
Hepatology (Baltimore, Md.); Wunsch E, Trottier J et. al.
Feb 12th, 2014 - Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10-15 mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, and fibroblast growth...
Lancet (London, England); Hegade VS, Kendrick SF et. al.
Feb 11th, 2017 - Up to 70% of patients with primary biliary cholangitis develop pruritus (itch) during the course of their disease. Treatment of pruritus in primary biliary cholangitis is challenging and novel therapies are needed. Ursodeoxycholic acid, the standard first-line treatment for primary biliary cholangitis, is largely ineffective for pruritus. We investigated the efficacy and safety of GSK2330672, a...
Clinical Gastroenterology and Hepatology : the Official C... Andersen IM, Tengesdal G et. al.
Sep 30th, 2013 - Little is known about nongenetic risk factors for primary sclerosing cholangitis (PSC), except a possible protective effect of smoking. We investigated the relationship between environmental risk factors and susceptibility to PSC. A questionnaire was distributed to patients with PSC, recruited from Oslo University Hospital Rikshospitalet in Norway through 2011, and randomly chosen individuals f...
Clinical Gastroenterology and Hepatology : the Official C... Zenouzi R, Weismüller TJ et. al.
Feb 17th, 2014 - Primary sclerosing cholangitis (PSC) is associated with an increased risk of hepatobiliary malignancies. However, little is known about the incidence of hepatocellular carcinoma (HCC) among patients with PSC; current recommendations on screening these patients for HCC are conflicting. We investigated the risk of HCC in patients with PSC with cirrhosis. We performed a retrospective study of pati...
PloS One; Shaheen AA, Kaplan GG et. al.
Apr 4th, 2018 - Depression is prevalent in primary biliary cholangitis (PBC) patients. Our aims were to examine the effects of depression and antidepressants on hepatic outcomes of PBC patients. We used the UK Health Improvement Network database to identify PBC patients between 1974 and 2007. Our primary outcome was one of three clinical events: decompensated cirrhosis, liver transplantation and death. We asse...
Hepatology (Baltimore, Md.); Deneau MR, Mack C et. al.
Sep 18th, 2020 - Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 1:1:1 to those treated with UDCA or managed with observation (no treatment) based on the clo...
Hepatology (Baltimore, Md.); Muir AJ, Levy C et. al.
Aug 28th, 2018 - Lysyl oxidase like-2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC). We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody directed against LOXL2, in patients with PSC. Patients with compensated liver disease caused by PSC were randomized 1:1:1 to receive weekly subcutaneous injections...
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Pockros PJ et. al.
Oct 13th, 2019 - Primary biliary cholangitis (PBC) is an autoimmune disease characterized by bile duct destruction that can progress to cirrhosis. A liver biopsy substudy was conducted in the PBC obeticholic acid (OCA) International Study of Efficacy (POISE) to determine the long-term effects of OCA on liver damage and fibrosis in patients with PBC. POISE is a phase 3, double-blind, placebo-controlled, randomiz...
Hepatology (Baltimore, Md.); Lindor KD, Bowlus CL et. al.
Aug 2nd, 2018 - Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.|2018|Lindor KD,Bowlus CL,Boyer J,Levy C,Mayo M,|complications,diagnosis,therapy,
The American Journal of Gastroenterology; Ahn DW, Lee SH et. al.
Apr 3rd, 2018 - In clinical practice, recurrent cholangitis due to residual common bile duct (CBD) stone occurs frequently even after endoscopic stone removal. This study aimed to determine whether preventive saline irrigation of the bile duct (PSIB) after endoscopic removal of CBD stones would decrease the residual CBD stones. In this multicenter, prospective, randomized study, patients who received endoscopi...
Gastrointestinal Endoscopy; Iqbal U, Khara HS et. al.
Oct 19th, 2019 - Acute cholangitis is characterized by abdominal pain, fever, and jaundice. Most patients respond to medical management with intravenous hydration and antibiotics. About 20% to 30% require biliary drainage, and ERCP is the procedure of choice. We conducted a systematic review and meta-analysis to evaluate the impact of emergent biliary drainage on patient outcomes. A comprehensive literature rev...
Gastroenterology de Vries E, Bolier R et. al.
Oct 8th, 2020 - Pruritus may seriously impair quality of life in patients with cholestatic diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary cholangitis (PBC). Pharmacologic strategies show limited efficacy and can provoke serious side effects. We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-asso...
Hepatology (Baltimore, Md.); Schramm C, Eaton J et. al.
May 30th, 2017 - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by inflammation and fibrosis of the intra- and/or extrahepatic bile ducts. Magnetic resonance imaging (MRI) is a noninvasive imaging modality that can be used to diagnose PSC and detect disease related complications. Quantitative MRI technologies also have the potential to provide valuable prognostic info...
Hepatology (Baltimore, Md.); Deneau MR, El-Matary W et. al.
Apr 8th, 2017 - There are limited data on the natural history of primary sclerosing cholangitis (PSC) in children. We aimed to describe the disease characteristics and long-term outcomes of pediatric PSC. We retrospectively collected all pediatric PSC cases from 36 participating institutions and conducted a survival analysis from the date of PSC diagnosis to dates of diagnosis of portal hypertensive or biliary...